Home › Compound Library › TB-500 (Thymosin Beta-4)

TB-500 (Thymosin Beta-4)

Peptidesubcutaneous · inferred

Synthetic fragment of thymosin beta-4, a 43-amino-acid protein involved in tissue repair and regeneration. Promotes angiogenesis, cell migration, and wound healing. Short plasma half-life but prolonged tissue-level effects. WADA-banned substance. Typically dosed at 2-5 mg 1-2x/week.

Projected serum levels — 2.5 mg, twice weekly

TB-500 (Thymosin Beta-4)
TB-500 (Thymosin Beta-4) modeled serum levels, 2.5 mg twice weekly over 18 days Population-based pharmacokinetic estimate. Steady state reached after approximately 4 days. 0 0.50 1 1.5 2 Day 0 Day 4 Day 9 Day 13 Day 18 Time on a regular schedule ≈ steady state · day 4

Maintenance schedule: 2.5 mg twice weekly (subcutaneous).

Modeled steady state after ~4 days: peak ≈ 1.9 mg, trough ≈ 0.000 mg body load. Population-based estimate over 18 days for a 2.5 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Peptide
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
1.9 h
Common dose
2.5 mg
Suggested maximum
5 mg/day
Reference dose range
1.3–5 mg (single dose)
Suggested cadence
twice weekly

Research behind this entry

  1. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers Ruff D et al. · Annals of the New York Academy of Sciences, 2010 DOI

    First-in-human IV dosing study of thymosin beta-4 in healthy volunteers demonstrating good tolerability at single doses up to 1260 mg and multiple daily doses up to 140 mg with no dose-limiting toxicities.

  2. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair Bock-Marquette I et al. · Nature, 2004 DOI

    Demonstrated that thymosin beta-4 promotes cardiac cell migration and survival through ILK activation, and treatment after coronary ligation in mice improved cardiac function and reduced scar formation.

  3. Simultaneous quantification of TB-500 and its metabolites by UHPLC-Q-Exactive orbitrap MS/MS and wound healing activities in vitro Rahaman JMM et al. · Journal of Chromatography B, 2024 DOI

    Identified 13 TB-500 metabolites using multiple enzymatic approaches and developed a sensitive assay for their detection, advancing understanding of TB-500 metabolism and clearance.

  4. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ruff D, Crockford D, Girardi G, Zhang Y · Annals of the New York Academy of Sciences, 2010 DOI

    This citation reports a human clinical study involving analogue or class evidence, not direct identity-level evidence for TB-500 (Thymosin Beta-4). The clinical study administered full-length thymosin beta-4, not…

4 published studies referenced in the app, each with a plain-language summary.